Switching from VEDOlizumab Intravenous to Subcutaneous Formulation in Ulcerative Colitis Patients in Clinical RemissionDavide Giuseppe Ribaldone2023PDF429 KB
Optimizing Antithrombotic Therapy in Patients with Coexisting Cardiovascular and Gastrointestinal DiseaseAzita Talasaz2024PDF1.8 MB
The Deleterious Effects of Shiga Toxin Type 2 Are Neutralized In Vitro by FabF8:Stx2 Recombinant Monoclonal AntibodyDaniela Luz, Fernando D. Gómez & 11 morePDF1.9 MBEN
Difficult-to-treat (DTR) Pseudomonas aeruginosa harboring Verona-Integron metallo-β-lactamase (blaVIM)Ana D. Vega & Kailynn DeRonde & Adriana Jimenez & Michael Piazza & Christine Vu & Octavio Martinez & Laura J. Rojas & Steven Marshall & Mohamad Yasmin & Robert A. Bonomo & Lilian M. Abbo2024PDF2.0 MBEN
Antiplatelet and Anticoagulant Therapy in the 2025 ACC-AHA Guideline for Acute Coronary Syndromes a 2025 BY American College of Cardiology FoundationBehnood Bikdeli MD Ms & Francisco Ujueta MD Ms & Sina Rashedi MD Mph & Azita H. Talasaz PharmD PhD & Kushal T. Kadakia MD Msc & Renato D. Lopes MD PhD & Harvey D. White Dsc & Philippe Gabriel Steg MD & Gregory Piazza MD Ms & Rasha K. Al-Lamee Mbbs PhD...2025PDF820 KBEN